This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Federal Service for Surveillance in Healthcare (Roszdravnadzor) | |
|---|---|
| Name | Federal Service for Surveillance in Healthcare |
| Native name | Федеральная служба по надзору в сфере здравоохранения |
| Formed | 2004 |
| Jurisdiction | Russian Federation |
| Headquarters | Moscow |
| Chief1 name | Veronika Skvortsova |
| Parent agency | Ministry of Health of the Russian Federation |
Federal Service for Surveillance in Healthcare (Roszdravnadzor) is a Russian federal executive authority responsible for oversight of medical care, pharmaceutical circulation, and public health safety. It conducts inspections, issues licenses and registrations, and enforces compliance with healthcare legislation across the Russian Federation, interacting with ministries, regional authorities, and international organizations. The agency traces its roots to post-Soviet reforms and operates within a legal regime shaped by statutes, decrees, and regulatory acts.
Roszdravnadzor was established amid administrative reforms in the early 2000s that reorganized federal supervisory bodies following precedents set by the Government of Russia and the Ministry of Health of the Russian Federation. Its formation in 2004 succeeded predecessor arrangements from the 1990s including functions once held by bodies linked to the Soviet Union healthcare administration and regional health directorates in Moscow Oblast. Over time, Roszdravnadzor’s remit expanded in response to crises such as the 2009 flu pandemic, the COVID-19 pandemic in Russia, and pharmaceutical safety incidents involving manufacturers like Pharmstandard and distributors tied to markets in Saint Petersburg and Kazan. Leadership changes have included figures with backgrounds in institutions such as the Sechenov University, the Russian Academy of Medical Sciences, and the Ministry of Health of the Russian Federation.
The agency operates under federal legislation including the Constitution of Russia, the Federal Law on Licensing of Certain Types of Activities, and statutes regulating pharmaceuticals such as the Federal Law on Circulation of Medicines. Presidential decrees and decrees of the Government of Russia define supervisory powers and coordination mechanisms with the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing and the Federal Customs Service. Roszdravnadzor’s legal mandate covers licensing of medical organizations, state registration of medicines and medical devices, control over clinical trials often involving institutions like Gamalei Research Institute of Epidemiology and Microbiology and Pirogov Russian National Research Medical University, and enforcement actions grounded in the Code of Administrative Offenses of Russia.
The central office in Moscow coordinates regional territorial bodies that align with federal subjects such as Moscow Oblast, Republic of Tatarstan, and Sverdlovsk Oblast. Executive leadership includes a director and deputies with professional links to academic centers including the Russian Academy of Sciences, the First Moscow State Medical University, and regulatory agencies like the Federal Antimonopoly Service (Russia). Internal departments handle licensing, pharmacovigilance, clinical oversight, accreditation, and legal matters; specialized units liaise with institutions such as the World Health Organization’s country office and international regulatory networks.
Roszdravnadzor conducts inspections of hospitals, clinics, and laboratories including facilities affiliated with Moscow State University hospitals and regional medical centers. It issues authorizations for medicines and medical devices following submissions often from manufacturers like Biocad and contract research organizations working with universities such as Saint Petersburg State University. Activities encompass pharmacovigilance, oversight of blood services linked to the Moscow Blood Center, supervision of clinical trial compliance involving research centers like Vector Institute, and control over sanitary-epidemiological welfare in cooperation with entities such as the Rospotrebnadzor. The service also manages adverse event reporting systems and implements quality control measures in line with standards influenced by the European Medicines Agency and bilateral arrangements with ministries in neighboring countries like Belarus.
Enforcement tools include suspension or revocation of licenses, administrative fines under the Code of Administrative Offenses of Russia, product recalls, and mandatory corrective actions. High-profile interventions have targeted pharmaceutical manufacturers, clinical trial sponsors, and private clinics in cities including Novosibirsk and Yekaterinburg. The agency has collaborated with prosecutors such as the General Prosecutor's Office of Russia and courts including the Supreme Court of Russia in litigation over regulatory decisions. Enforcement outcomes have affected supply chains tied to importers in Kaliningrad and exporters to markets like Kazakhstan.
Roszdravnadzor engages with the World Health Organization, the Council of Europe, and regional bodies such as the Eurasian Economic Union on harmonization of pharmaceutical regulation and cross-border health threats. It has signed memoranda of understanding with counterparts including the European Medicines Agency, the Chinese National Medical Products Administration, and the Food and Drug Administration-linked entities in cooperative research, pharmacovigilance, and information exchange. Multilateral initiatives have involved partnerships with universities like Heidelberg University and institutes such as the Pasteur Institute for capacity building and joint scientific projects.
The agency has faced criticism from healthcare associations, patient advocacy groups, and media outlets over inspection practices, transparency of licensing decisions, and handling of clinical trial approvals. Controversial matters have included disputes with pharmaceutical companies like R-Pharm over registration refusals, allegations regarding oversight of private clinics in Sochi, and debates over emergency approvals during public health crises such as the COVID-19 pandemic in Russia. Legal challenges have proceeded through administrative courts and drawn commentary from human rights organizations and professional bodies including the Russian Medical Association.
Category:Government agencies of Russia Category:Health regulatory agencies